Johnson & Johnson (JNJ) is currently trading at $255.63. Based on 22 Wall Street analysts, the average target price is $270.59, implying a 5.9% upside. The consensus recommendation is BUY.

JNJ

Johnson & Johnson

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$255.63

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$263.00$300.00
Current $255.63
Median: $278.00Mean: $279.58Current: $255.63

Recent price target updates (latest 80)

  • GuggenheimJul 17, 2026

    PT action: Maintains

    $270.00 → $270.00

  • Raymond JamesJul 16, 2026

    PT action: Raises

    $258.00 → $265.00

  • RBC CapitalJul 16, 2026

    PT action: Maintains

    $287.00 → $287.00

  • Wells FargoJul 16, 2026

    PT action: Raises

    $263.00 → $272.00

  • Morgan StanleyJul 16, 2026

    PT action: Raises

    $284.00 → $294.00

  • TD CowenJul 13, 2026

    PT action: Raises

    $250.00 → $300.00

  • RBC CapitalJul 13, 2026

    PT action: Raises

    $265.00 → $287.00

  • B of A SecuritiesJul 10, 2026

    PT action: Raises

    $254.00 → $263.00

  • Morgan StanleyJul 8, 2026

    PT action: Raises

    $283.00 → $284.00

  • CitigroupJul 8, 2026

    PT action: Raises

    $285.00 → $298.00

  • GuggenheimJun 26, 2026

    PT action: Raises

    $266.00 → $270.00

  • Leerink PartnersMay 13, 2026

    PT action: Announces

    $0.00 → $265.00

  • BarclaysApr 15, 2026

    PT action: Raises

    $234.00 → $255.00

  • StifelApr 15, 2026

    PT action: Raises

    $220.00 → $250.00

  • Wells FargoApr 15, 2026

    PT action: Raises

    $240.00 → $263.00

  • Morgan StanleyApr 10, 2026

    PT action: Raises

    $262.00 → $267.00

  • RBC CapitalMar 30, 2026

    PT action: Maintains

    $255.00 → $255.00

  • BarclaysMar 19, 2026

    PT action: Raises

    $217.00 → $234.00

  • HSBCMar 17, 2026

    PT action: Raises

    $265.00 → $280.00

  • CitigroupMar 11, 2026

    PT action: Raises

    $250.00 → $274.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$270.59

Based on 22 analysts

Analyst Recommendations

Buy (16)Hold (6)Sell (1)

Upside

+5.85%

Market Cap

$615.36B

Financial & Investment Metrics

Next Earnings Date
Oct 13, 2026D-83
P/E Ratio (TTM)29.66
Forward P/E19.91
P/B Ratio7.58
Dividend Yield2.14%
Return on Equity (ROE)N/A
Operating Margin28.61%
Debt to Equity67.73
Beta (Volatility)0.23
52 Week Range$164.23 - $269.43
LowCurrent: $255.63High

Latest News

Daily editorial mentioning JNJ

Price target moves

Healthcare and Tech Dominate as 24 Target Revisions Hit the Wire

The latest sentiment shift across the S&P 500 has been active, with 24 distinct ticker price targets adjusted over the last 14 days, according to data as of July 13, 2026. The activity is concentrated in the Healthcare and IT sectors, where institutional analysts are re-evaluating long-term valuation models despite recent price volatility.

Target changes

The moves reflect a mix of cautious recalibration and optimistic outlooks. UBS was particularly busy, issuing a series of upward revisions for healthcare heavyweights. Notably, the firm boosted LLY from 1250 to 1425 and VRTX from 545 to 585. Meanwhile, TD Cowen took a more selective approach, raising ADI to 460 from 450 while simultaneously lowering its outlook on ISRG twice in the same window—first to 600 and then to 520, signaling significant disagreement within the firm's own modeling trajectory.

Ticker Firm Dir Prior → Current
TSLA Jefferies Up 375 → 400
ISRG TD Cowen Down 585 → 520
FTNT TD Cowen Up 160 → 215
NFLX Oppenheimer Down 120 → 100

Industrial names also saw downward pressure, as TD Cowen trimmed its targets for both LMT and NOC, moving them to 560 and 580, respectively. In the communication services space, the outlook remains fragmented; while UBS lowered GOOGL to 400, the broader market volatility has left some price action feeling disconnected from recent fundamental adjustments.

How this differs from consensus

When we look at the spread between these new targets and the current consensus mean, it is clear that some analysts are leaning into extreme outcomes. For instance, the recent downgrade of NFLX to 100 by Oppenheimer sits at a striking variance compared to the broader market's expectations. This move suggests a fundamental questioning of subscriber growth narratives that the consensus has yet to fully internalize. Conversely, the aggressive upward revision for FTNT to 215 by TD Cowen highlights a divergence in how analysts account for cyber-security demand, placing the firm far ahead of the average valuation model. These target adjustments serve as a reminder that institutional consensus is often a lagging indicator, prone to rapid shifts when firm-level analysts pivot their core growth assumptions.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
7/20/2026BROADHURST VANESSAOfficerSale at price 251.27 per share.23,054
6/11/2026WENGEL KATHRYN EChief Technology OfficerSale at price 241.15 per share.10,000
2/27/2026DECKER ROBERT JOfficerSale at price 247.87 per share.4,075
2/20/2026SCHMID TIMOTHYOfficerSale at price 245.66 per share.1,322
2/18/2026SCHMID TIMOTHYOfficerSale at price 244.20 - 244.53 per share.22,623
2/17/2026SWANSON JAMES DChief Technology OfficerSale at price 242.70 - 243.76 per share.62,080
2/17/2026BROADHURST VANESSAOfficerSale at price 243.39 per share.6,197
2/17/2026WOLK JOSEPH JChief Financial OfficerSale at price 242.68 - 242.99 per share.89,654
2/17/2026REED JOHN COfficerSale at price 243.00 per share.53,931
1/26/2026DUATO JOAQUIN BOIXChief Executive OfficerSale at price 220.99 - 221.48 per share.100,000

Frequently Asked Questions

Q. What is the current target price and upside for JNJ?

A. The current target price for Johnson & Johnson is $270.59, which implies a 5.9% upside from the current price of $255.63. This is based on the consensus of 22 Wall Street analysts.

Q. What is the current analyst recommendation for JNJ?

A. Currently, there are 5 Strong Buy, 11 Buy, 6 Hold, 1 Sell, and 0 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying JNJ stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer